Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
JPMorgan Chase & Co. filed an amended Schedule 13G reporting its beneficial ownership in Cartesian Therapeutics, Inc. (common stock). The firm reports beneficial ownership of 1,486,252 shares of common stock, representing 4.8% of the class as of June 30, 2026. JPMorgan Chase & Co. has sole voting power over 1,397,213 shares and sole dispositive power over 1,486,252 shares, with no shared voting or dispositive power. The filing notes that this represents ownership of 5 percent or less of the class, and identifies JPMorgan Chase Bank, National Association, and J.P. Morgan Investment Management Inc. as relevant subsidiaries.
Key Figures
Beneficial ownership:1,486,252 sharesPercent of class:4.8%Sole voting power:1,397,213 shares+3 more
6 metrics
Beneficial ownership1,486,252 sharesCommon stock of Cartesian Therapeutics beneficially owned by JPMorgan Chase & Co.
Percent of class4.8%Portion of Cartesian Therapeutics common stock class held by JPMorgan Chase & Co.
Sole voting power1,397,213 sharesShares of Cartesian Therapeutics over which JPMorgan Chase & Co. has sole voting power
Shared voting power0 sharesShares of Cartesian Therapeutics over which JPMorgan Chase & Co. has shared voting power
Sole dispositive power1,486,252 sharesShares of Cartesian Therapeutics over which JPMorgan Chase & Co. has sole dispositive power
Shared dispositive power0 sharesShares of Cartesian Therapeutics over which JPMorgan Chase & Co. has shared dispositive power
Key Terms
Schedule 13G, beneficially owned, sole voting power, sole dispositive power, +1 more
5 terms
Schedule 13Gregulatory
"JPMORGAN CHASE & CO. filed an amended Schedule 13G reporting its beneficial ownership"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole voting powerfinancial
"Sole Voting Power 1,397,213.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive powerfinancial
"Sole Dispositive Power 1,486,252.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
percent of classfinancial
"Percent of class: 4.8 %"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Cartesian Therapeutics (RNAC) does JPMorgan Chase & Co. report owning?
JPMorgan Chase & Co. reports beneficial ownership of 4.8% of the outstanding common stock of Cartesian Therapeutics, Inc. This corresponds to 1,486,252 shares of common stock as disclosed in the amended Schedule 13G for the position as of June 30, 2026.
How many Cartesian Therapeutics (RNAC) shares does JPMorgan Chase & Co. beneficially own?
JPMorgan Chase & Co. reports beneficial ownership of 1,486,252 shares of Cartesian Therapeutics common stock. This share amount represents 4.8% of the class, with all 1,486,252 shares subject to sole dispositive power and a slightly smaller number subject to sole voting power.
What voting power does JPMorgan Chase & Co. have over its Cartesian Therapeutics (RNAC) shares?
JPMorgan Chase & Co. has sole voting power over 1,397,213 shares of Cartesian Therapeutics common stock. It reports no shared voting power, indicating that decisions on voting these shares are controlled solely by entities within JPMorgan Chase & Co.
Does JPMorgan Chase & Co. share dispositive power over any Cartesian Therapeutics (RNAC) shares?
No. JPMorgan Chase & Co. reports sole dispositive power over 1,486,252 shares and zero shared dispositive power. This means only JPMorgan-related entities decide if and when these shares are sold or otherwise disposed of, according to the filing.
Which JPMorgan Chase & Co. subsidiaries are identified in the Cartesian Therapeutics (RNAC) Schedule 13G/A?
The filing identifies JPMorgan Chase Bank, National Association and J.P. Morgan Investment Management Inc. as relevant subsidiaries. These entities are associated with acquiring or holding the reported Cartesian Therapeutics common stock for JPMorgan Chase & Co.
Is JPMorgan Chase & Co. reporting ownership above or below 5% in Cartesian Therapeutics (RNAC)?
JPMorgan Chase & Co. reports ownership of 4.8% of the class, explicitly categorized as ownership of 5 percent or less. This level keeps the position below the 5% threshold commonly used for certain additional disclosure and reporting requirements.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Cartesian Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
816212302
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
816212302
1
Names of Reporting Persons
JPMORGAN CHASE & CO.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,397,213.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,486,252.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,486,252.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.8 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Cartesian Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
7495 New Horizon Way Frederick MD 21703
Item 2.
(a)
Name of person filing:
JPMORGAN CHASE & CO.
(b)
Address or principal business office or, if none, residence:
270 Park Avenue,,New York, NY 10017
(c)
Citizenship:
DE
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP No.:
816212302
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
1486252
(b)
Percent of class:
4.8 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
1397213
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
1486252
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
JPMorgan Chase Bank, National Association;
J.P. Morgan Investment Management Inc.
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
